JP2014502973A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502973A5
JP2014502973A5 JP2013548628A JP2013548628A JP2014502973A5 JP 2014502973 A5 JP2014502973 A5 JP 2014502973A5 JP 2013548628 A JP2013548628 A JP 2013548628A JP 2013548628 A JP2013548628 A JP 2013548628A JP 2014502973 A5 JP2014502973 A5 JP 2014502973A5
Authority
JP
Japan
Prior art keywords
composition
toll
receptor
cancer
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013548628A
Other languages
English (en)
Japanese (ja)
Other versions
JP6041444B2 (ja
JP2014502973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/020844 external-priority patent/WO2012097012A1/en
Publication of JP2014502973A publication Critical patent/JP2014502973A/ja
Publication of JP2014502973A5 publication Critical patent/JP2014502973A5/ja
Application granted granted Critical
Publication of JP6041444B2 publication Critical patent/JP6041444B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013548628A 2011-01-10 2012-01-10 癌を治療するためのＴｏｌｌ様受容体アゴニストの使用 Expired - Fee Related JP6041444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431313P 2011-01-10 2011-01-10
US61/431,313 2011-01-10
PCT/US2012/020844 WO2012097012A1 (en) 2011-01-10 2012-01-10 Use of toll-like receptor agonist for treating cancer

Publications (3)

Publication Number Publication Date
JP2014502973A JP2014502973A (ja) 2014-02-06
JP2014502973A5 true JP2014502973A5 (enExample) 2015-03-05
JP6041444B2 JP6041444B2 (ja) 2016-12-07

Family

ID=46507417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548628A Expired - Fee Related JP6041444B2 (ja) 2011-01-10 2012-01-10 癌を治療するためのＴｏｌｌ様受容体アゴニストの使用

Country Status (15)

Country Link
US (7) US9376473B2 (enExample)
EP (1) EP2663367A4 (enExample)
JP (1) JP6041444B2 (enExample)
KR (1) KR20140030132A (enExample)
CN (1) CN103476458B (enExample)
AU (1) AU2012205681B2 (enExample)
BR (1) BR112013017283A2 (enExample)
CA (1) CA2824438A1 (enExample)
CL (1) CL2013002001A1 (enExample)
CO (1) CO6781506A2 (enExample)
EA (1) EA026524B1 (enExample)
IL (1) IL227308A (enExample)
MX (2) MX361355B (enExample)
SG (1) SG191830A1 (enExample)
WO (1) WO2012097012A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2663367A4 (en) * 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2014098649A1 (en) * 2012-12-18 2014-06-26 Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" Compositions and methods using toll-like receptor 5 and toll-like receptor agonist
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN104258375A (zh) * 2014-09-18 2015-01-07 中国人民解放军军事医学科学院放射与辐射医学研究所 辐抗肽蛋白的新用途
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
US10717767B2 (en) 2017-07-20 2020-07-21 Spogen Biotech, Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN108478782B (zh) * 2018-05-16 2021-05-18 中国人民解放军军事科学院军事医学研究院 辐抗肽在促肝细胞再生中的应用
CN108404113A (zh) * 2018-05-16 2018-08-17 中国人民解放军军事科学院军事医学研究院 用于抗辐射损伤的口服辐抗肽药物组合物
US12440536B2 (en) * 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
CN111109198B (zh) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 一种葡萄膜炎动物模型构建方法
WO2021041822A1 (en) * 2019-08-30 2021-03-04 Genome Protection. Inc. Methods of increasing vaccine efficacy
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
EP4175640A1 (en) 2020-07-02 2023-05-10 VIIV Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CA3198114A1 (en) * 2020-11-09 2022-05-12 Jung-Joon Min Salmonella strain for prevention and treatment of cancer and use thereof
KR102543157B1 (ko) * 2020-11-16 2023-06-14 아주대학교산학협력단 톨-유사 수용체 1/2 및/또는 4 활성화 펩타이드 및 이의 용도
CN114592007B (zh) * 2022-04-29 2023-10-27 昆明理工大学 Far1基因的新用途
CN117281906B (zh) * 2023-10-18 2026-06-26 浙江大学 Csrnp1抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用
EP4620482A1 (en) * 2024-03-18 2025-09-24 Istituto Europeo di Oncologia S.r.l. Flagellin-related peptides and uses thereof
WO2025196053A1 (en) 2024-03-18 2025-09-25 Istituto Europeo Di Oncologia S.R.L. Flagellin-related peptides and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
DE59107966D1 (de) 1990-09-28 1996-08-01 Sulzer Innotec Ag Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
AU4709401A (en) 1999-11-29 2001-06-12 Inotek Corporation Composition and method for treating a microbial infection
JP2003527109A (ja) 2000-01-31 2003-09-16 ミューニン コーポレイション ヒトｃｙｒ６１
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US8580321B2 (en) 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
EP1706133B1 (en) 2003-12-02 2010-10-06 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) * 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
WO2006081007A2 (en) 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
JP5285278B2 (ja) 2004-12-22 2013-09-11 クリーブランド クリニック ファウンデイション フラゲリン関連ポリペプチドおよびその使用
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20070269406A1 (en) * 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
US20110182847A1 (en) * 2007-06-15 2011-07-28 Randolph Noelle Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
EP2178896A1 (en) 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
JP5577337B2 (ja) 2008-08-01 2014-08-20 クリーブランド バイオラブス， インコーポレイテッド 再灌流傷害を治療するための方法
AU2010250923A1 (en) 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2486134B1 (en) 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2663367A4 (en) * 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER

Similar Documents

Publication Publication Date Title
PH12017500484B1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
PH12018500189A1 (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
PH12018500848A1 (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
PH12018500864A1 (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
MY181449A (en) Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
PH12017501275A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
CR20200556A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE MAMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0135)
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
WO2013192423A3 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX2020011787A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
MY198087A (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
Sossa Rojas Estudio del potencial oncolítico del aislamiento rotaviral humano Wt1-5 en adenocarcinoma gástrico
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
PH12012501935A1 (en) Ect2 peptides and vaccines including the same
Daifu et al. CD146 is a novel marker of highly tumorigenic populations and a therapeutic target in malignant rhabdoid tumor
NZ770913A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EA202092542A2 (ru) Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака